A Exploratory Trial of WTX221 in Refractory Gout Patients
Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This trial is a single-center, open-label designed investigator-initiated clinical study
(IIT) to investigate the safety, tolerability, PK, PD, immunogenicity, and preliminary
efficacy of multiple doses of WTX221 infusion combined with a single dose of the
immunosuppressive agent cyclophosphamide (CTX) to induce immune tolerance.
The trial consisted of a Screening Period (14 days), a First Dose Period (30 days), a Second
Dose Period (30 days), and a Safety Follow-up Period (150 days) for a total of 224 days.